Showing 91-100 of 9221 results for "".
- SGR Patch: AADA Disappointed By Congressional Actionhttps://practicaldermatology.com/news/20140401-sgr_patch_aada_disappointed_by_congressional_action/2459285/Statement from Brett M. Coldiron, MD, FAAD President, American Academy of Dermatology Association: The U.S. House of Representatives and Senate have averted a 24 percent cut in Medicare physician payments by agreeing to a one-year short-term measure (HR 4302) to maintain current Medicare payment r
- Alphaeon Acquires US License To Teoxane Laboratories' Dermal Fillers And Cosmeceutical Productshttps://practicaldermatology.com/news/20130802-alphaeon_acquires_us_license_to_teoxane_laboratories_dermal_fillers_and_cosmeceutical_products/2459484/Alphaeon Corporation, a wholly-owned subsidiary of Strathspey Crown Holdings, LLC, has acquired an exclusive US license for the full line of products from Teoxane Laboratories. Containing 100 percent non-animal origin, resorbable hyaluronic acid, Teoxane's dermal fillers are currently available in m
- New Jersey Passes Law Prohibiting Indoor Tanning for Those Under 17https://practicaldermatology.com/news/20130402-new_jersey_passes_law_prohibiting_indoor_tanning_for_those_under_17/2459575/The state of New Jersey recently passed a law that bans minors under the age of 17 years old from using indoor tanning devices. The law passed both the New Jersey House and Senate in February and was signed into law by Gov. Christopher Christie on April 1, 2013. Dirk M. Elston, MD, FAAD, President o
- NEA Expands Seal of Acceptance Program to Makeup Productshttps://practicaldermatology.com/news/nea-expands-seal-of-acceptance-program-to-makeup-products/2488269/The National Eczema Association (NEA) has expanded its Seal of Acceptance program to include color cosmetics, opening the program to makeup products for the first time since the Seal was established in 2008. The initial expan
- Cuttlefish Ink-Derived Microneedles Show Potential for Vitiligo Repigmentationhttps://practicaldermatology.com/news/cuttlefish-ink-derived-microneedles-show-potential-for-vitiligo-repigmentation/2488260/Researchers have developed a fast-dissolving microneedle platform designed to address oxidative stress, inflammation, melanocyte loss, and depigmentation in vitiligo, according to a preclinical study published in Marine Life Scie
- Maternal and Infant Skin Microbiomes Show Distinct but Connected Developmenthttps://practicaldermatology.com/news/maternal-and-infant-skin-microbiomes-show-distinct-but-connected-development/2488255/The skin microbiomes of mothers and their infants appear to be closely connected during early life, although infant microbial diversity follows its own developmental trajectory, according to a recent longitudinal study published in Experimental Dermatology. Researchers for the stu
- Medical Creators Produce Higher-Quality Alopecia Areata Content on Social Media: Studyhttps://practicaldermatology.com/news/medical-creators-produce-higher-quality-alopecia-areata-content-on-social-media/2488252/A cross-sectional study of alopecia areata content on 3 major Chinese social media platforms found that video quality, reliability, and adherence to clinical guidance varied substantially by platform and creator background. Investigators evaluated 111 high-engagement educational videos ide
- Hidradenitis Suppurativa Linked to Higher Cardiovascular Risk: Meta-Analysishttps://practicaldermatology.com/news/hidradenitis-suppurativa-linked-to-higher-cardiovascular-risk-meta-analysis/2488190/Hidradenitis suppurativa (HS) was associated with increased risk of multiple cardiovascular outcomes in a systematic review and meta-analysis encompassing 373,689 individuals with the chronic inflammatory skin disease. Cardiovascular Comorbidities and Hidradenitis Suppurativa
- INTerpath-001: Intismeran Plus Pembrolizumab Meets Dual Phase 3 Melanoma Endpointshttps://practicaldermatology.com/news/intismeran-plus-pembrolizumab-meets-dual-phase-3-melanoma-endpoints/2488176/Merck and Moderna reported positive topline results from the phase 3 INTerpath-001 trial evaluating intismeran autogene (V940; mRNA-4157) plus pembrolizumab (Keytruda) as adjuvant therapy for completely resected stage IIB-IV cutaneous melanoma. The individualized mRNA-based neoantigen ther
- Occupational Exposures Implicated in More Than Half of Chronic Hand Eczema Caseshttps://practicaldermatology.com/news/occupational-exposures-implicated-in-more-than-half-of-chronic-hand-eczema-cases/2488120/A new retrospective study of adults with chronic hand eczema (CHE) found allergic contact dermatitis (ACD) and occupational exposures were common, while most patients improved following diagnosis and treatment recommendations that included allergen avoidance. Investigators evaluated 76 adu